News Channels

06 Dec 2023 Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
06 Dec 2023 BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
06 Dec 2023 Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
06 Dec 2023 Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
06 Dec 2023 Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
06 Dec 2023 AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
06 Dec 2023 Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
06 Dec 2023 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
06 Dec 2023 Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)
06 Dec 2023 Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
05 Dec 2023 U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothel
05 Dec 2023 FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
05 Dec 2023 Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
05 Dec 2023 GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
05 Dec 2023 Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
05 Dec 2023 CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
05 Dec 2023 Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference
05 Dec 2023 Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
05 Dec 2023 Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
05 Dec 2023 Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up